Shots:

• The US FDA has been granted BTD for the treatment of patients with ROS1+ metastatic NSCLC who have not been treated with ROS1 TKI-naïve
• The designation is based on P-I & P-II portion of TRIDENT-1 study of repotrectinib in TKI-naïve ROS1-positive NSCLC patients. The study is currently evaluating patients in multiple potentially registrational cohorts
• The company plans to report updated P-II TRIDENT-1 study results in patients with TKI-naive ROS1-positive NSCLC at the World Conference on Lung Cancer on Jan 31- 2021

 ­ Ref: GlobeNewswire | Image: Biocom